doi:10.1001/jamanetworkopen.2024.57349 NICE (2025) Quality statement 7: Advice and support after stopping medicines for weight management or completing behavioural interventions (Accessed: 10 August 2025)
Research presented Monday at a large diabetes meeting showed some promise for this approach
Tel +49 (5042) 940 - 670 oder 0 800 - 3 38 23 55 (gebhrenfrei aus Deutschland) Fax +49 (5042) 940 - 238 Unser Team vom EUCELL Gesundheitsservice erreichen Sie montags bis freitags von 08:00 bis 16:00 Uhr
The STEP trials (semaglutide) and SURMOUNT trials (tirzepatide) enrolled thousands of participants and demonstrated that GLP-1 therapy produces meaningful, sustained weight loss across diverse populations, with acceptable safety profiles when used under medical supervision
At Perfect B in Doral, the intake consultation is where the right patients are identified, the protocol is built, and the expectations are set correctly from the start
Moreover, the researchers commented that Ipamorelin appears to be the first GHS-R agonist with a selectivity for GH release similar to that displayed by GHRH